Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
VANCOUVER, British Columbia, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, today announced the signing of a supply agreement with Sunshine Earth Labs Ltd. (“Sunshine Labs”), a fellow British Columbia-based biosciences company licensed by Health Canada.
- VANCOUVER, British Columbia, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, today announced the signing of a supply agreement with Sunshine Earth Labs Ltd. (“Sunshine Labs”), a fellow British Columbia-based biosciences company licensed by Health Canada.
- This strategic collaboration marks a significant milestone for both Optimi and Sunshine Labs, who share a commitment to ensuring a secure global supply of GMP quality-controlled substances for medicinal and research purposes.
- Optimi CEO, Bill Ciprick, says the partnership will forge a formidable alliance as both companies leverage their points of access in the highly regulated psychedelics market.
- Donovan Edwards, CEO of Sunshine Labs, echoes the sentiment, saying, "Our partnership with Optimi solidifies our commitment to delivering a safe and secure supply of controlled substances globally.